Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib

A 63-year-old woman with pulmonary adenocarcinoma (stage IIIB) that was positive for an epidermal growth factor receptor (EGFR) mutation and an anaplastic lymphoma kinase (ALK) rearrangement was treated with erlotinib as the first-line treatment, resulting in a stable disease. Due to skin rashes, fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Akira, Tamura, Atsuhisa, Miyakawa, Kazuko, Kusaka, Kei, Shimada, Masahiro, Hirose, Takashi, Matsui, Hirotoshi, Kitani, Masashi, Hebisawa, Akira, Ohta, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148164/
https://www.ncbi.nlm.nih.gov/pubmed/29526950
http://dx.doi.org/10.2169/internalmedicine.0383-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148164/
https://www.ncbi.nlm.nih.gov/pubmed/29526950
http://dx.doi.org/10.2169/internalmedicine.0383-17

Ejemplares similares